You know the more I think about ftt the more I think it’s a compelling investment case.
$30M market cap for a company with a phase two trial well under way. If successful it is a potential platform for launching the product in Europe and a pharma deal for phase 3 in the us. Plus a pipeline of products for other indications.
Yes they will probably have to raise a little money before the trial readout, but they have the capability to do this quickly and efficiently to sophisticated investors when the time comes.
If you hear a beeping noise, it might just be me backing up the truck.
- Forums
- ASX - By Stock
- DLM
- Ann: Clinical Trial Update
Ann: Clinical Trial Update, page-12
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DLM (ASX) to my watchlist
|
|||||
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.227M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
DLM (ASX) Chart |
Day chart unavailable